乌龙制药 URGN 深 沪
等待开盘 12-30 09:30:00 美东时间
23.33
+0.300
+1.30%
华盛通- 最 高23.34
- 今 开23.00
- 成交量 46.06万股
- 最 低 22.50
- 昨 收 23.03
- 总市值 10.92亿
- 52周最高 30.00
- 市盈率 静 --
- 换手率 0.98%
- 52周最低 3.42
- 委 比 -92.78%
- 总股本 4680.89万
- 历史最高 69.568
- 量 比 1.00
- 振 幅 3.65%
- 历史最低 3.42
- 每 手 1
- 风险率 5.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股周涨跌榜 | Capricor周涨402.6%，核心药物取得关键性临床试验进展；DBRG周涨45.4%，曝软银有意收购
Capricor周涨402.6%，核心药物取得关键性临床试验进展；DBRG周涨45.4%，曝软银有意收购；UiPath本周上涨34.7%，财报表现强劲>>
12-06 10:17
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. granted inducement RSUs to 14 new employees, supporting the commercialization of Jelmyto® and ZUSDURI™ and pipeline development. Up to 32,500 shares are issuable, vesting over three years. The RSUs align with UroGen’s commitment to advancing innovative urothelial cancer treatments.
12-05 13:00
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
UroGen Pharma Ltd., a biotech company focused on developing innovative treatments for urothelial and specialty cancers, announced its participation in the Piper Sandler 37th Annual Healthcare Conference on December 2-4, 2025, in New York, NY. The company will host a fireside chat on December 2, 2025, at 1:00 PM ET. Webcast links and replays will be available on UroGen’s Investor Relations website for 90 days. UroGen specializes in creating sustai...
11-25 13:00
UroGen Pharma’s ZUSDURI Launch Drives Q3 Growth
Urogen Pharma ( ($URGN) ) has released its Q3 earnings. Here is a breakdown of ...
11-07 13:54
UroGen Pharma Q3 EPS $(0.69), Inline, Sales $27.500M Miss $33.093M Estimate
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.69) per share which met the analyst consensus estimate. This is a 25.45 percent decrease over losses of $(0.55) per share from the same period last year. The
11-06 21:02
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
UroGen Pharma reported Q3 2025 financial results, highlighting strong performance of ZUSDURI with $1.8M net revenue and a $4.5M demand estimate in October. JELMYTO contributed $25.7M revenue, up 13% YoY. UGN-103 showed a 77.8% complete response rate, aligning with ENVISION results, with FDA agreement on NDA submission. Cash reserves stood at $127.4M. A conference call was scheduled for further updates.
11-06 13:00
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
UroGen Pharma Ltd. announced its participation in the Guggenheim Securities Healthcare Innovation Conference on November 11, 2025, in Boston, featuring a presentation and investor meetings. The company, focused on innovative treatments for urothelial and specialty cancers, will also provide a webcast available on its Investor Relations website for 90 days.
11-04 13:00
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $40 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $40 price target.
10-27 23:22
